AVACTA GROUP PLC ORD GBP0.10AA

AVACTA GROUP PLC ORD GBP0.10

38.00GBXD
+0.50+1.33%
At close at May 30, 16:06 GMT
GBX
No trades
See on Supercharts

AVCT fundamentals

Key facts

Market capitalization‪146.82 M‬GBP
Founded2003
CEOChristina Marie Coughlin
Websiteavacta.com
About

Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceutical companies. It operates through the Life Sciences and Animal Health segments. The Life Sciences segment offers custom Affimers for reagents and diagnostics, drug and biomarker discovery in biotech research and development. The Animal Health segment includes tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company was founded by Alastair MacLaughlin Smith, Simon Webster, and Kurt Justin Baldwin in 2003 and is headquartered in Leeds, the United Kingdom.

Ownership
‪‪383.45 M‬‬
Free Float shares
‪‪376.08 M‬‬ (98.08%)
Closely held shares
‪‪7.37 M‬‬ (1.92%)
Free Float shares
‪‪376.08 M‬‬ (98.08%)
Closely held shares
‪‪7.37 M‬‬ (1.92%)
Capital structure
No data available
There's currently no data to show about this capital structure.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪146.82 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
Valuation ratios
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪5.00‬
‪10.00‬
‪15.00‬
‪20.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−775%‬
‪−605%‬
‪−435%‬
‪−265%‬
‪−95%‬
H2 '22
H1 '23
H2 '23
H1 '24
‪‪−36.00 M‬‬
‪‪−24.00 M‬‬
‪‪−12.00 M‬‬
‪0.00‬
‪‪12.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
No data available
There's currently no revenue data to show for the selected period.

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Diagnostics
Therapeutics
By country
Period: 2023
United Kingdom
France
Rest of Europe
South Korea
Rest of World
North America

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪‪3.00 M‬‬
‪‪6.00 M‬‬
‪‪9.00 M‬‬
‪‪12.00 M‬‬
Actual
Estimate
Earnings
Next:Sep 3, 2025
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪−0.04‬
‪−0.03‬
‪−0.02‬
‪−0.01‬
‪0.00‬
Actual

Dividends

Dividend yield, history and sustainability

No dividends
AVCT has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−21.00 M‬‬
‪0.00‬
‪‪21.00 M‬‬
‪‪42.00 M‬‬
‪‪63.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
Assets
Liabilities